The historical rank and industry rank for China Pharma Holding's FCF Margin % or its related term are showing as below:
CPHI'
s FCF Margin % Range Over the Past 10 Years
Min: -15.41 Med: -3.44 Max: 17.36
Current: 2.18
During the past 13 years, the highest FCF Margin % of China Pharma Holding was 17.36%. The lowest was -15.41%. And the median was -3.44%.
CPHI's FCF Margin % is ranked worse than 51.04% of 962
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs CPHI: 2.18
China Pharma Holding FCF Margin % Related Terms
China Pharma Holding FCF Margin % Historical Data
* Premium members only.
The historical data trend for China Pharma Holding's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Pharma Holding FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's FCF Margin % distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding (CPHI) has a FCF Margin % of -5.59% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on China Pharma Holding and its competitors. According to the industry distribution chart, China Pharma Holding ranks #491 out of 962 companies in the Drug Manufacturers industry, placing it in the top 51%.
Is China Pharma Holding's FCF Margin % too high?
China Pharma Holding's current FCF Margin % is -5.59%. Based on the distribution chart, China Pharma Holding ranks #491 out of 962 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, China Pharma Holding has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's FCF Margin % compare to TXMD and RMTI?
According to the Drug Manufacturers industry distribution chart, China Pharma Holding ranks #491 out of 962 companies for FCF Margin %. This places China Pharma Holding in the lower half of its industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on China Pharma Holding and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Pharma Holding's current FCF Margin % is -5.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
Based on GuruFocus' analysis, China Pharma Holding (CPHI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.57 — trading 137.5% above its estimated fair value. The current FCF Margin % is -5.59%. China Pharma Holding's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For China Pharma Holding (CPHI), the current FCF Margin % is -5.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Pharma Holding (CPHI) Overvalued in 2026?
Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued.
The current stock price of $0.57 is trading 137.5% above its estimated GF Value™ of $0.24.
GuruFocus considers China Pharma Holding to be Significantly Overvalued.
Key valuation signals for CPHI:
FCF Margin %: -5.59%
GF Value™: $0.24 vs. price of $0.57 (137.5% above fair value)
No single metric tells the full story. See the CPHI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score
Get the complete analysis for CPHI
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHI has been successfully added to your 
